Publications by authors named "D Langley"

The emergence of SARS-CoV-2 variants of concern (VOCs) has greatly diminished the neutralizing activity of previously FDA-approved monoclonal antibodies (mAbs), including that of antibody cocktails and of first-generation broadly neutralizing antibodies such as S309 (Sotrovimab). In contrast, antibodies targeting cryptic conformational epitopes of the receptor binding domain (RBD) have demonstrated broad activity against emerging variants, but exert only moderate neutralizing activity, which has so far hindered clinical development. Here, we utilize in vitro display technology to identify and affinity-mature antibodies targeting the cryptic class 6 epitope, accessible only in the "up" conformation of the SARS-CoV-2 spike trimer.

View Article and Find Full Text PDF

Diphenhydramine (DPH), a readily available first-generation H1 receptor antihistamine, can have severe consequences when taken in excessive amounts and can lead to grave outcomes such as seizures, dysrhythmias, coma, and death. Recognizing the early signs and symptoms of DPH toxicity is crucial. Fortunately, fatal adult cases of DPH overdose are rare.

View Article and Find Full Text PDF

Molar pregnancy is a topic in emergency medicine frequently tested and regularly discussed but is perhaps overshadowed by other conditions such as ectopic pregnancy. It is a rare diagnosis encountered in the emergency department (ED) and is part of a broad spectrum of pathological conditions that fall into the category of gestational trophoblastic disease (GTD). Diagnosis of this potentially malignant condition requires the emergency physician to bear this condition in mind when treating any woman while considering obstetric-related conditions in the first trimester, vaginal bleeding, pelvic pain or pressure, and excessive nausea and vomiting.

View Article and Find Full Text PDF

Non-sustained ventricular tachycardia (NSVT) poses significant risks during pregnancy, particularly in patients with underlying conditions such as β-thalassemia. We present a case of a 29-year-old pregnant woman with a history of β-thalassemia minor who experienced NSVT at 27 weeks gestation. Despite initial concerns for structural heart disease, the workup was unrevealing.

View Article and Find Full Text PDF
Article Synopsis
  • Estrogen receptor (ER) alpha is a key factor in ER+/HER2- breast cancer, and combining current therapies with new drugs is essential due to resistance issues like ESR1 mutations.
  • Vepdegestrant (ARV-471) is a new drug that efficiently degrades both wild-type and mutant ER, showing significant tumor growth inhibition in various breast cancer models, outperforming the standard treatment fulvestrant.
  • The study suggests that vepdegestrant could be a more effective treatment option for patients with ER+/HER2- breast cancer, especially when combined with other therapies like CDK4/6, mTOR, or PI3K inhibitors.
View Article and Find Full Text PDF